Walleye Capital
DNLI icon

Walleye Capital’s Denali Therapeutics DNLI Stock Holding History

Walleye Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-700
Closed -$11.6K – 4523
2025
Q4 		$11.6K Buy
+700
New +$11.8K ﹤0.01% 4291
2024
Q1 		– Sell
-1,600
Closed -$34.3K – 5499
2023
Q4 		$34.3K Buy
+1,600
New +$31.7K ﹤0.01% 4386

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's DNLI Position: Q1 2026 in Review

Walleye Capital sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 12,652 shares — an estimated $209K sold.

Walleye Capital first reported a position in DNLI in Q4 2020 and held it in 6 quarters. The position peaked at $910K in Q1 2022. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Walleye Capital reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 12,652 Denali Therapeutics shares in Q1 2026, an estimated $209K.
  • Walleye Capital first reported a position in Denali Therapeutics in Q4 2020 and held it in 6 quarters.
  • Walleye Capital's Denali Therapeutics position peaked at $910K in Q1 2022.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.